New Clinical Findings Highlight Potential for Vision Protection in Geographic Atrophy

For members of the inherited retinal disease and broader retinal community, advancements in neuroprotection and preserving foundational eye structures represent critical milestones. Recently reported data from the Phase 2 ARCHER study indicate that an investigational therapy, ANX007, significantly reduced the risk of vision loss for patients suffering from geographic atrophy, an advanced form of dry age-related macular degeneration (AMD).

According to reports from drugdiscoverytrends.com and presentations at the 128th annual meeting of the American Academy of Ophthalmology (AAO 2024), monthly injections of ANX007 cut the risk of significant vision loss by 72%.

Key Findings from the Phase 2 Study

  • Risk Reduction: Patients treated with a monthly 5 mg dose of ANX007 demonstrated a 72% reduced risk of losing three or more lines of vision on an eye chart after one year. Patients treated every other month experienced a 48% reduction in risk.
  • Mechanism of Action: ANX007 is designed as a novel neuroprotective agent that targets the complement system by blocking the C1q immune molecule, which is implicated in driving neurodegeneration, inflammation, and synapse loss.
  • Anatomical Preservation: Data showed that the treatment helped preserve key retinal structures, including photoreceptors in the central fovea and a reduction in ellipsoid zone area loss.

What This Means for Patients and Families

Geographic atrophy causes regions of retinal cells to waste away, creating expanding blind spots that interfere with everyday activities such as reading, recognizing faces, and driving. While regulatory bodies like the U.S. Food and Drug Administration (FDA) have previously approved therapies that help slow disease progression, there remain limited options focused specifically on protecting functional vision from this condition. The data showing both anatomical preservation and a lowered risk of visual acuity loss offer encouraging signals for individuals navigating advanced dry AMD.

Looking Ahead

Building on these Phase 2 results, a global, randomized, sham-controlled Phase 3 trial designated as ARCHER II is currently underway. Topline data from this subsequent study are anticipated in the second half of 2026. Additionally, ANX007 has earned Fast Track status from the FDA and Priority Medicine (PRIME) designation within the European Union to support its ongoing clinical development.